NewsBenzingaSummit Therapeutics, AstraZeneca And Daiichi Sankyo Announce Clinical Trial Collaboration To Evaluate Ivonescimab With TROP2-Directed ADC Datroway Across Multiple Tumor Types, Starting With Phase III First-Line Triple-Negative Breast Cancer Study Summit Therapeutics, AstraZeneca And Daiichi Sankyo Announce Clinical Trial Collaboration To Evaluate Ivonescimab With TROP2-Directed ADC Datroway Across Multiple Tumor Types, Starting With Phase III First-Line Triple-Negative Breast Cancer Study Benzinga 2026.10.02 06:36 (GMT+0) Open on Benzinga Other news Nike, Synaptics And 3 Stocks To Watch Heading Into Friday S&P 500 Edges Higher As Treasury Yields Retreat: Investor Sentiment Declines, Fear & Greed Index Remains In ‘Fear’ Zone Nike Just Admitted Its China Problem Is About to Get Worse, With $230 Billion in Market Cap Already Gone — CEO Elliott Hill Warns the Pain Isn't Over Gavin Newsom Cracks Down on Robotaxis After Emergency Disruptions — New California Law Could Hit Waymo and Tesla With Penalties Full Transcript: RenaissanceRe Holdings Q2 2026 Earnings Call Cloudflare Opens Tokenization Gateway to Closed Beta, Supporting Pay-Per-Use Billing for AI Agents
S&P 500 Edges Higher As Treasury Yields Retreat: Investor Sentiment Declines, Fear & Greed Index Remains In ‘Fear’ Zone
Nike Just Admitted Its China Problem Is About to Get Worse, With $230 Billion in Market Cap Already Gone — CEO Elliott Hill Warns the Pain Isn't Over
Gavin Newsom Cracks Down on Robotaxis After Emergency Disruptions — New California Law Could Hit Waymo and Tesla With Penalties
